Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

Alnylam Pharmaceuticals (ALNY) reported strong Q3 2025 financial results, significantly exceeding analyst expectations with $1.25 billion in revenue, a 149.4% year-over-year increase, and EPS of $2.90. This outperformance was primarily driven by robust growth in Amvuttra net product revenue, which surged 165% to $685.3 million, despite a 22.3% decline in Onpattro revenue. The company's shares have recently outperformed the S&P 500, currently holding a Zacks Rank #3 (Hold).

Analysis

Alnylam Pharmaceuticals (ALNY) reported exceptionally strong Q3 2025 financial results, significantly surpassing analyst expectations. The company posted $1.25 billion in revenue, marking a substantial 149.4% year-over-year increase and a +22.25% surprise over the $1.02 billion consensus estimate. Earnings per share (EPS) reached $2.90, a remarkable turnaround from -$0.50 a year prior and a +73.65% beat against the $1.67 consensus.

This robust performance was primarily driven by Amvuttra, which saw net product revenue surge by 165% year-over-year to $685.3 million, exceeding the $637.51 million estimate. While Oxlumo also contributed positively with a 31.4% year-over-year increase to $52.83 million, Onpattro's net product revenue declined by 22.3% year-over-year to $39.08 million, missing estimates. Givlaari also missed estimates slightly, growing only 4% year-over-year.

Despite some product-specific misses, overall product revenues, net, grew 102.6% to $851.08 million, beating estimates. The stock has outperformed the broader market, returning +4.6% over the past month compared to the S&P 500's +3.6%. The current Zacks Rank #3 (Hold) suggests the stock is expected to perform in line with the market in the near term.

Key Decisions for Investors

• Investors should acknowledge Alnylam's significant Q3 outperformance driven by strong overall revenue and EPS beats, but closely monitor the sustainability of Amvuttra's growth as a primary revenue driver.
• Evaluate the implications of the shifting product mix, particularly the robust growth in Amvuttra offsetting the notable decline in Onpattro, for long-term revenue diversification and pipeline strength.
• Consider the stock's recent outperformance and the Zacks Rank #3 (Hold) in conjunction with the strong earnings report, suggesting a balanced approach to position sizing and continued due diligence on future guidance.